Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market

Reuters

2025/05/21

Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market

Evofem Biosciences Inc., a leader in women's health innovation, has entered into a partnership with Pharma 1 Drug Store LLC, a private Emirati healthcare company. The collaboration involves a License and Supply Agreement granting Pharma 1 exclusive rights to commercialize SOLOSEC® (secnidazole) in the Middle East. SOLOSEC is an FDA-approved, single-dose oral treatment for bacterial vaginosis and trichomoniasis, two prevalent sexual health conditions. Pharma 1 plans to submit for regulatory approval of SOLOSEC in the UAE by mid-2025. The agreement includes upfront and milestone-based payments to Evofem, and Pharma 1 will handle all regulatory, distribution, sales, marketing, and commercial functions in the region. This partnership aims to leverage Pharma 1's focus on sexual health to effectively launch SOLOSEC in the UAE and surrounding areas.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA93046) on May 21, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537482933"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537482933\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537482933?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-21 20:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537482933","market":"us","top_or_hot":-1,"title":"Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Evofem Biosciences Inc., a leader in women's health innovation, has entered into a partnership with Pharma 1 Drug Store LLC, a private Emirati healthcare company. The collaboration involves a License and Supply Agreement granting Pharma 1 exclusive rights to commercialize SOLOSEC® (secnidazole) in the Middle East. SOLOSEC is an FDA-approved, single-dose oral treatment for bacterial vaginosis and trichomoniasis, two prevalent sexual health conditions. Pharma 1 plans to submit for regulatory approval of SOLOSEC in the UAE by mid-2025. The agreement includes upfront and milestone-based payments to Evofem, and Pharma 1 will handle all regulatory, distribution, sales, marketing, and commercial functions in the region. This partnership aims to leverage Pharma 1's focus on sexual health to effectively launch SOLOSEC in the UAE and surrounding areas.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA93046) on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-21 20:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Evofem Biosciences Inc., a leader in women's health innovation, has entered into a partnership with Pharma 1 Drug Store LLC, a private Emirati healthcare company. The collaboration involves a License and Supply Agreement granting Pharma 1 exclusive rights to commercialize SOLOSEC® (secnidazole) in the Middle East. SOLOSEC is an FDA-approved, single-dose oral treatment for bacterial vaginosis and trichomoniasis, two prevalent sexual health conditions. Pharma 1 plans to submit for regulatory approval of SOLOSEC in the UAE by mid-2025. The agreement includes upfront and milestone-based payments to Evofem, and Pharma 1 will handle all regulatory, distribution, sales, marketing, and commercial functions in the region. This partnership aims to leverage Pharma 1's focus on sexual health to effectively launch SOLOSEC in the UAE and surrounding areas.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA93046) on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVFM","symbol_name":"Evofem Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL9xRfBk:1","article_id":"2537482933","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537482933","pubTimestamp":1747832358,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evofem Biosciences Inc., a leader in women's health innovation, has entered into a partnership with Pharma 1 Drug Store LLC, a private Emirati healthcare company. The collaboration involves a License and Supply Agreement granting Pharma 1 exclusive rights to commercialize SOLOSEC  in the Middle East. SOLOSEC is an FDA-approved, single-dose oral treatment for bacterial vaginosis and trichomoniasis, two prevalent sexual health conditions. Pharma 1 plans to submit for regulatory approval of SOLOSEC in the UAE by mid-2025. The agreement includes upfront and milestone-based payments to Evofem, and Pharma 1 will handle all regulatory, distribution, sales, marketing, and commercial functions in the region. This partnership aims to leverage Pharma 1's focus on sexual health to effectively launch SOLOSEC in the UAE and surrounding areas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVFM":"Evofem Biosciences, Inc.","BK4007":"制药","BK4584":"避孕概念"},"translate_title":"Evofem Biosciences与Pharma 1合作将SOLOSEC引入中东市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVFM":0.9},"content_text":"Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market\n    \n\n        Evofem Biosciences Inc., a leader in women's health innovation, has entered into a partnership with Pharma 1 Drug Store LLC, a private Emirati healthcare company. The collaboration involves a License and Supply Agreement granting Pharma 1 exclusive rights to commercialize SOLOSEC® (secnidazole) in the Middle East. SOLOSEC is an FDA-approved, single-dose oral treatment for bacterial vaginosis and trichomoniasis, two prevalent sexual health conditions. Pharma 1 plans to submit for regulatory approval of SOLOSEC in the UAE by mid-2025. The agreement includes upfront and milestone-based payments to Evofem, and Pharma 1 will handle all regulatory, distribution, sales, marketing, and commercial functions in the region. This partnership aims to leverage Pharma 1's focus on sexual health to effectively launch SOLOSEC in the UAE and surrounding areas.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA93046) on May 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}